Prof. Nordeng appointed by European Commission as independent scientific expert in PRAC
The Pharmacovigilance Risk Assessment Committee (PRAC) is the European Medicines Agency's (EMA) committee responsible for assessing and monitoring the safety of human medicines.
The PRAC is responsible for assessing all aspects of risk management of human medicines, including:
- the detection, assessment, minimisation and communication of the risk of adverse reactions, while taking the therapeutic effect of the medicine into account;
- design and evaluation of post-authorisation safety studies;
- pharmacovigilance audit.
The committee meets monthly in London. In addition to Hedvig Nordeng, the following scientific experts were appointed:
Birgitta Grundmark, Uppsala Monitoring Centre
Antoine Pariente, Université de Bordeaux
Livia Puljak, University of Split School of Medicine (not present in photo)
Stefan Weiler, University of Zurich
Daniel Morales, University of Dundee
We wish Prof. Nordeng good luck in her work in PRAC!